Payment overview · 2025
General Payments
$384.29
14 reported records · 8 companies
Healthcare provider profile · identity verified
Jennifer Iris James, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAWTON, OK · NPI 1801156609
Verified facts
What the public records show
CMS Open Payments records show Jennifer Iris James, MD received $384.29 in general payments during 2025 across 14 reported records.
HISTOSONICS, INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HISTOSONICS, INC. | Unresolved — no canonical attribution shown | $150.00 | 39.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.53 | 18.1% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $45.25 | 11.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.83 | 9.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.81 | 8.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.00 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.31 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.56 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $384.29 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.86 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $45.25 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 404 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 88 |
| Omeprazole | Omeprazole | 244 | 68 |
| Gabapentin | Gabapentin | 243 | 68 |
| Losartan Potassium | Losartan Potassium | 217 | 73 |
| Potassium Chloride | Potassium Chloride | 200 | 64 |
| Alprazolam | Alprazolam | 198 | 36 |
| Furosemide | Furosemide | 185 | 59 |
| Lisinopril | Lisinopril | 183 | 57 |
| Metformin Hcl | Metformin Hcl | 182 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 51 |
| Montelukast Sodium | Montelukast Sodium | 182 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 37 |
| Ozempic | Semaglutide | 122 | 24 |
| Trazodone Hcl | Trazodone Hcl | 117 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 27 |
| Carvedilol | Carvedilol | 109 | 33 |
| Eliquis | Apixaban | 106 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 30 |
| Simvastatin | Simvastatin | 95 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 17 |
| Tramadol Hcl | Tramadol Hcl | 89 | 20 |
| Meloxicam | Meloxicam | 86 | 30 |
| Sertraline Hcl | Sertraline Hcl | 81 | 22 |
| Pregabalin | Pregabalin | 80 | 18 |
| Prednisone | Prednisone | 79 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Metformin Hcl Er | Metformin Hcl | 73 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Celecoxib | Celecoxib | 70 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 15 |
| Farxiga | Dapagliflozin Propanediol | 67 | 17 |
| Diazepam | Diazepam | 66 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 15 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Azithromycin | Azithromycin | 64 | 39 |
| Glipizide | Glipizide | 62 | 16 |
| Allopurinol | Allopurinol | 61 | 20 |
| Clonazepam | Clonazepam | 61 | 16 |
| Alendronate Sodium | Alendronate Sodium | 59 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 16 |
| Fluconazole | Fluconazole | 55 | 21 |
| Bupropion Xl | Bupropion Hcl | 54 | 18 |
| Synthroid | Levothyroxine Sodium | 54 | 13 |
| Sucralfate | Sucralfate | 53 | 14 |
| Atenolol | Atenolol | 52 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 17 |
| Temazepam | Temazepam | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 13 |
| Amoxicillin | Amoxicillin | 47 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 24 |
| Ondansetron Odt | Ondansetron | 45 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 15 |
| Ibuprofen | Ibuprofen | 41 | 15 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Estradiol | Estradiol | 38 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 22 |
| Linzess | Linaclotide | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 25 |
| Nifedipine Er | Nifedipine | 34 | 13 |
| Donepezil Hcl | Donepezil Hcl | 32 | 11 |
| Jardiance | Empagliflozin | 32 | 11 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 16 |
| Methylprednisolone | Methylprednisolone | 29 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Baclofen | Baclofen | 28 | 11 |
| Famotidine | Famotidine | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Nystatin | Nystatin | 24 | 17 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $384.29 · 14 records | HISTOSONICS, INC. | AIRSUPRA, CAPVAXIVE, ELIQUIS, FARXIGA, GARDASIL 9, M-M-R II, NURTEC ODT, TRELEGY ELLIPTA, VOWST, VRAYLAR, ZENPEP, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error